Abstract 2597
Background
Cancer holds a huge psychosocial impact. Understanding the diagnosis and treatment gives cancer patients a feeling of autonomy and self-control. The patients’ perspective and expectations on the qualities of a medical oncologist are still poorly known.
Methods
Observational cross-sectional study of cancer patients observed in a Portuguese peripheral hospital in October 2018. When patients knew the primary tumour site, stage of disease and intent of treatment they were considered to have “Full knowledge”. Descriptive statistics and univariate analysis were performed, considering a CI of 95%.
Results
Seventy-two patients were included. Most were men (56.9%), with a median age of 60 years and 65.3% had an ECOG PS of 1. Patients reported feelings of shock (43.0%), sadness (38.9%), fear (34.7%) and courage (33.3%) when they became aware of their oncological diagnosis. About 12.5% of patients needed evaluation by Psychology/Psychiatry on the first 3 months after diagnosis, of which 2/3 had a history of depressive or anxiety disorders. The majority of patients (78%) received the diagnosis in a consultation, 12.5% in the emergency department with 4.2% being informed by their relatives (4.2%). About 90% of patients stated they knew their diagnosis while 5.6% were not sure. Correct identification of the primary tumour site occurred in 87% of patients and 81.9% knew the disease stage. Of those under treatment (n = 58), almost 20% did not understand its intention. About 54% of patients had "full knowledge" of the disease and treatments. There was no significant correlation between socio-demographic and clinical variables and "full knowledge" of the disease, and only age approached the significance level (p = 0.083). Patients mostly valued kindness (62.5%), honesty (55.6%) and knowledge (47.2%) in a medical oncologist.
Conclusions
Despite the majority of patients claiming to be aware of their disease, almost half did not understand the disease stage or treatment intention. Clear communication can contribute to a greater sense of knowledge, autonomy and adaptation to the disease, potentially influencing quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract